Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Stopped Sponsor-PI decision. An analysis of the primary endpoint concluded that the addition of ribociclib to standard of care enzalutamide did not demonstrate benefit, an all active subjects were removed from the study.

Conditions

• Castration-Resistant Prostate Carcinoma
• Metastatic Prostate Carcinoma
• Prostate Carcinoma Metastatic in the Bone
• Stage IV Prostate Cancer AJCC v7

Interventions

• DRUG: Enzalutamide
• DRUG: Ribociclib
• OTHER: Laboratory Biomarker Analysis
• OTHER: Pharmacological Study
• PROCEDURE: Biospecimen Collection
• PROCEDURE: Biopsy
• PROCEDURE: Echocardiography
• PROCEDURE: Multigated Acquisition Scan
• PROCEDURE: Bone Scan
• PROCEDURE: Computed Tomography
• PROCEDURE: Magnetic Resonance Imaging

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Collaborators

• [object Object]
• [object Object]